Browse the evidence

hASC from subjects harboring Ad-36 DNA show greater differentiation ability compared to Ad-36 DNA-negative counterparts.

Understanding the impact of Ad-36 on differentiation may inform obesity treatment strategies.

Rosiglitazone treatment exacerbated lipid accumulation and decreased insulin-stimulated glucose transport in skeletal muscle.

Caution is advised when using rosiglitazone, as it may worsen lipid metabolism and insulin sensitivity.

There were no significant differences in markers of oxidative stress (urinary isoprostanes, serum protein carbonyls, or DNA fragmentation) between the age groups.

Oxidative stress may not accumulate with age as previously thought, impacting health aging strategies.

OSM acts on adipocytes to induce the expression and secretion of plasminogen activator inhibitor 1 and IL-6.

Understanding OSM's role could help in developing strategies to modulate inflammation in obesity.

ALA was not associated with T2D risk.

Practitioners should note that ALA does not appear to reduce T2D risk, unlike other n-3 fatty acids.

Skeletal muscle extracellular matrix remodeling may contribute to the development of metabolic dysfunction associated with energy excess and obesity.

Understanding muscle remodeling may help address metabolic issues related to obesity.

A novel combination of common variants of HRAS1, LASS1, and APOE is associated with human lifespan and healthy aging.

Practitioners may consider the genetic profiles of HRAS1, LASS1, and APOE when assessing longevity and healthy aging.

An HRAS1 haplotype enhances the effect of an APOE haplotype on exceptional survival.

Understanding the genetic interactions may help in developing strategies for promoting longevity.

Mean PSA doubling time (PSADT) was similar between LCD (22 months) and control (15 months, P = 0.313) arms.

A low-carbohydrate diet does not adversely affect PSA doubling time in men with recurrent prostate cancer.

Immobilization does not alter mitochondrial H2O2 emission or markers of cellular redox state.

This suggests that oxidative stress may not be a significant factor in muscle atrophy during immobilization.

Pima Indians have lower fasting plasma magnesium concentration than Caucasians (0.79 +/- 0.05 vs. 0.85 +/- 0.06 mmol/L; P < 0.01).

Lower magnesium levels in Pima Indians may have implications for their metabolic health and insulin sensitivity.

Passive, low-intensity stretch does not appear to confer beneficial changes in muscle size and architecture.

Practitioners should avoid relying solely on passive stretching for muscle growth.

Moderate-intensity aerobic exercise does not induce satellite cell expansion.

Moderate-intensity aerobic exercise may not be sufficient for muscle health in older adults.

Rifaximin treatment for 6 weeks did not result in significant changes in alanine aminotransferase (ALT) levels in patients with NASH (55 [33-191] vs. 63 [41-218] IU/L, P = 0.41).

Rifaximin may not be effective for reducing liver inflammation in NASH patients based on ALT levels.

After 12 weeks from baseline, serum ALT levels increased significantly to 83 (30-217) IU/L (P = 0.02).

Monitoring ALT levels is important as they may worsen after rifaximin treatment in NASH patients.

Recent clinical trials have not observed significant effects of n-3 PUFA supplementation on cardiovascular disease (CVD) events.

This suggests that n-3 PUFA supplementation may not be effective for CVD prevention in recent studies.

There was no significant change in telomere length at 6 months.

Weight loss interventions may not affect telomere length in the short term.

There is a need for more research on the anabolic potential of non-animal-derived protein sources.

More research is needed to evaluate the effectiveness of non-animal protein sources for muscle health.

INV-202 was well tolerated with no serious or severe treatment-emergent adverse events.

INV-202 appears to be a safe option for individuals with metabolic syndrome.

PLIN3 knockdown results in drastic reductions in lipid oxidation in myotubes from lean individuals.

Reducing PLIN3 may significantly impair lipid oxidation in lean muscle cells, which could impact metabolic health.

Greater male variation in basal energy expenditure may be explained by greater male variation in the size of energy-demanding organs.

Understanding organ size variation may help tailor nutritional strategies for energy expenditure.

Inter- and intradevice variation exists between DXA instruments, affecting data analysis in clinical trials.

Practitioners should be aware of potential measurement variability when using DXA in clinical trials.

Quality control procedures should be implemented prior to initiating clinical trials using DXA.

Implementing quality control can enhance the reliability of DXA measurements in trials.

Inter- and intrascan variability can be compounded by the patient population being investigated.

Understanding patient population effects can improve the interpretation of DXA results.